• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumour-necrosis-factor antibody treatment in Crohn's disease.

作者信息

Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, van Deventer S

出版信息

Lancet. 1993 Jul 17;342(8864):173-4. doi: 10.1016/0140-6736(93)91375-v.

DOI:10.1016/0140-6736(93)91375-v
PMID:8101267
Abstract
摘要

相似文献

1
Tumour-necrosis-factor antibody treatment in Crohn's disease.肿瘤坏死因子抗体治疗克罗恩病。
Lancet. 1993 Jul 17;342(8864):173-4. doi: 10.1016/0140-6736(93)91375-v.
2
Maintenance treatment for Crohn's disease: has the time arrived?克罗恩病的维持治疗：时机已到？
Am J Gastroenterol. 1992 May;87(5):551-6.
3
[Medical treatment of Crohn's disease].[克罗恩病的医学治疗]
Nihon Shokakibyo Gakkai Zasshi. 2000 Feb;97(2):145-52.
4
[Treatment of Crohn's disease].[克罗恩病的治疗]
Ther Umsch. 2003 Mar;60(3):159-63. doi: 10.1024/0040-5930.60.3.159.
5
Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
N Engl J Med. 1998 Jan 29;338(5):334. doi: 10.1056/NEJM199801293380515.
6
Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.病例报告：粒细胞单采术与英夫利昔单抗联合治疗难治性克罗恩病
J Clin Apher. 2006 Dec;21(4):249-51. doi: 10.1002/jca.20093.
7
[Infliximab-induced hepatitis in a patient with Crohn's disease].
Gastroenterol Hepatol. 2006 May;29(5):321-2. doi: 10.1157/13087475.
8
Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.抗肿瘤坏死因子α抗体治疗克罗恩病。
Lancet. 2000 Mar 11;355(9207):858-60. doi: 10.1016/S0140-6736(99)00442-0.
9
Anti-TNF antibody treatment of Crohn's disease.抗TNF抗体治疗克罗恩病。
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I114-20. doi: 10.1136/ard.58.2008.i114.
10
Tumour necrosis factor and Crohn's disease.肿瘤坏死因子与克罗恩病
Gut. 1997 Apr;40(4):443-8. doi: 10.1136/gut.40.4.443.

引用本文的文献

1
Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease.迈向精准医学：炎症性肠病中对托法替布反应的分子生物标志物
Genes (Basel). 2025 Jul 29;16(8):908. doi: 10.3390/genes16080908.
2
Long-Term Response Durability of Infliximab for Pediatric Inflammatory Bowel Disease in Japan: A Single Center Experience.英夫利昔单抗治疗日本儿童炎症性肠病的长期反应持久性：单中心经验
Pediatr Gastroenterol Hepatol Nutr. 2025 May;28(3):166-175. doi: 10.5223/pghn.2025.28.3.166. Epub 2025 May 8.
3
A Characterization of the Humoral Immune Response to Human Endogenous Retroviruses and in Crohn's Disease.
克罗恩病中针对人类内源性逆转录病毒的体液免疫反应的特征
Pathogens. 2025 Apr 7;14(4):361. doi: 10.3390/pathogens14040361.
4
Different fibroblast subtypes propel spatially defined ileal inflammation through TNFR1 signalling in murine ileitis.在小鼠回肠炎中，不同的成纤维细胞亚型通过TNFR1信号传导推动空间定义的回肠炎症。
Nat Commun. 2025 Mar 28;16(1):3023. doi: 10.1038/s41467-025-57570-7.
5
Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data.炎症性肠病患者英夫利昔单抗剂量优化的治疗药物监测：加拿大真实世界数据分析
Can J Gastroenterol Hepatol. 2025 Feb 6;2025:5713315. doi: 10.1155/cjgh/5713315. eCollection 2025.
6
Early intervention with Ustekinumab is associated with higher rates of clinical and endoscopic remission in patients with Crohn's disease.对于克罗恩病患者，早期使用乌司奴单抗进行干预与更高的临床缓解率和内镜缓解率相关。
Therap Adv Gastroenterol. 2024 Dec 23;17:17562848241307596. doi: 10.1177/17562848241307596. eCollection 2024.
7
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.抗肿瘤坏死因子治疗炎症性肠病的纵向单细胞图谱。
Nat Immunol. 2024 Nov;25(11):2152-2165. doi: 10.1038/s41590-024-01994-8. Epub 2024 Oct 22.
8
Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients.抗生素会影响中国炎症性肠病患者接受抗TNF治疗期间形成抗药抗体的风险。
Front Pharmacol. 2024 Apr 9;15:1360835. doi: 10.3389/fphar.2024.1360835. eCollection 2024.
9
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000.生物制剂时代炎症性肠病的治疗策略变化：来自日本远东 1000 多中心队列的结果。
Sci Rep. 2023 Aug 21;13(1):13555. doi: 10.1038/s41598-023-40624-5.
10
Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab.食欲素 A 治疗实验性结肠炎炎症 flares 和黏膜愈合的疗效：与抗 TNF-α 英夫利昔单抗的比较。
Int J Mol Sci. 2023 May 31;24(11):9554. doi: 10.3390/ijms24119554.